Condensed Consolidated Statements of Operations (Unaudited) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2022	Dec. 31, 2021
Sales, net	$ 12,254	$ 14,594	$ 24,580	$ 27,345
Cost of sales	11,184	12,844	22,513	24,171
Gross profit	1,070	1,750	2,067	3,174
Selling and administrative expenses	1,103	1,020	2,070	1,859
Operating (loss) income	(33)	730	(3)	1,315
Other income (expense), net
Interest expense	(12)	(42)	(25)	(74)
Realized loss on sale of investment in iBio Stock	(35)	0	(35)	0
Unrealized gain (loss) on investments	31	(22)	27	(42)
Other income, net	4	25	7	31
Other income (expense), net	(12)	(39)	(26)	(85)
(Loss) income before income taxes	(45)	691	(29)	1,230
Income tax (expense) benefit, net	(10)	340	(61)	317
Net income	$ (55)	$ 1,031	$ (90)	$ 1,547
Basic earnings per common share (in dollars per share)	$ (0.00)	$ 0.04	$ (0.00)	$ 0.05
Diluted earnings per common share (in dollars per share)	$ 0.03	$ 0.03	$ 0.05	$ 0.05
Weighted average common shares outstanding - basic (in shares)	29,949,610	29,823,919	29,929,610	29,823,029
Add: Equivalent shares outstanding - Stock Options (in shares)	0	2,623,104	0	2,617,930
Weighted average common shares outstanding - diluted (in shares)	29,949,610	32,447,023	29,929,610	32,440,959